Nexien Biopharma Stock Probability Of Bankruptcy
| NXEN Stock | USD 0.01 0.01 35.00% |
Nexien |
Nexien Biopharma Company odds of distress Analysis
Nexien Biopharma's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Nexien Biopharma Probability Of Bankruptcy | Over 75% |
Most of Nexien Biopharma's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nexien Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Nexien Biopharma probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Nexien Biopharma odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Nexien Biopharma financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Nexien Biopharma has a Probability Of Bankruptcy of 75%. This is 73.25% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The probability of bankruptcy for all United States stocks is 88.3% lower than that of the firm.
Nexien Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nexien Biopharma's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Nexien Biopharma could also be used in its relative valuation, which is a method of valuing Nexien Biopharma by comparing valuation metrics of similar companies.Nexien Biopharma is currently under evaluation in probability of bankruptcy category among its peers.
Nexien Fundamentals
| Return On Equity | -40.7 | |||
| Return On Asset | -5.99 | |||
| Current Valuation | 2.58 M | |||
| Shares Outstanding | 62.77 M | |||
| Shares Owned By Insiders | 54.17 % | |||
| Price To Book | 205.41 X | |||
| EBITDA | (563.99 K) | |||
| Net Income | (626.36 K) | |||
| Cash And Equivalents | 116.9 K | |||
| Total Debt | 221.73 K | |||
| Debt To Equity | 0.36 % | |||
| Current Ratio | 0.51 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (75.14 K) | |||
| Earnings Per Share | (0.01) X | |||
| Beta | 1.48 | |||
| Market Capitalization | 1.95 M | |||
| Total Asset | 124.52 K | |||
| Z Score | -8.4 | |||
| Net Asset | 124.52 K |
About Nexien Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nexien Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nexien Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nexien Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Nexien Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nexien Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nexien Biopharma will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Nexien Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nexien Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nexien Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nexien Biopharma to buy it.
The correlation of Nexien Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nexien Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nexien Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nexien Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Nexien Pink Sheet
Nexien Biopharma financial ratios help investors to determine whether Nexien Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nexien with respect to the benefits of owning Nexien Biopharma security.